FDA于2026年5月20日向上海复宏汉霖签发483并列出11项观察项
FDA483:上海某知名生物药厂
FDA于2026年5月11日至20日检查上海复宏汉霖生物技术股份有限公司徐汇区宜山路1289号厂区,随后在5月20日签发483,共列出11项观察项。观察项指出三个PPQ批次可见异物剔除率持续升高并超过预设目检接受标准,缺陷调查取样缺乏书面论证,目检接受标准未经批准的变更控制即被追溯修改。
同一件事,精选收录的是《FDA 公布上海复宏汉霖 483 检查报告,检查列 11 项观察》
本文中观点不代表任何公司和组织,如有觉得有冒犯的地方,请于后台联系,我会及时删除。所有分享案例都具有孤立性,仅供参考。
皆为FDA官网披露,就算联系我删了,也没啥意义,而且国内的缺陷,我一般不批注……
FDA昨天一天就披露出了158份483……
其中国内就十几份,FDA自从上一任局长离职后,每个月都是几百人入职,感觉人手现在是充沛到不行……
表头信息 / Header Information
字段(Field) | 内容(Content) |
企业名称(Firm Name) | Shanghai Henlius Biopharmaceutical Co., Ltd. 上海复宏汉霖生物技术股份有限公司 |
街道地址(Street Address) | No. 1289, Yishan Rd, Xuhui District 上海市徐汇区宜山路 1289 号 |
城市、州、邮编、国家(City, State, ZIP Code, Country) | Shanghai, 200233, China 中国上海市,200233 |
受检机构类型(Type Establishment Inspected) | Drug Substance and Drug Product Manufacturer 原料药与制剂生产商 |
检查日期(Date(s) of Inspection) | 05/11/2026–05/20/2026 2026年5月11日—5月20日 |
签发日期(Date Issued) | 05/20/2026 2026年5月20日 |
检查员信息
Jie He, Senior Regulatory Specialist 【中文译文】何洁,高级法规专员
Xiaoshi Wang, PhD, Senior Pharmaceutical Scientist 【中文译文】王效实,博士,高级制药科学家
Jiangsong Jiang, PhD, Pharmaceutical Scientist 【中文译文】蒋江松,博士,制药科学家
检查结果:据说过了(今天FDA inspection data dashboard网站挂了,后面刻意看下)
观察项 1 / Observation 1
Your firm failed to demonstrate that the manufacturing process remained in a state of control and was capable of consistently producing drug product meeting established quality attributes during process performance qualification (PPQ) for xxx mg/xxx mL presentation. Specifically, your firm manufactured three PPQ batches (#xxx of xxx mg/xxx mL presentation). These batches exhibited increasingly high overall rejection rates at xxx %, xxx % and xxx % respectively during 100% xxx visual inspection. The rejection rates for major defects were xxx %, xxx % and xxx % for the three batches mainly due to visible particulates. The rejection rates for batches xxx xxx exceeded your pre-defined xxx % acceptance criterion for major visual inspection defects. These results indicate that the PPQ batches did not adequately demonstrate process consistency, reproducibility, and continued control with respect to visible particulate defects.
【中文译文】你方未能证明在工艺性能确认(PPQ)期间,生产工艺持续处于受控状态,并能够稳定生产出符合既定质量属性的制剂。具体而言,你方生产了三个 PPQ 批次(#xxx,规格为 xxx mg/xxx mL)。在 100% xxx 目检中,这三个批次的总体剔除率分别呈持续上升趋势,达到 xxx %、xxx % 和 xxx %。三个批次的主要缺陷剔除率分别为 xxx %、xxx % 和 xxx %,主要原因为可见异物。批次 xxx xxx 的剔除率超过了你方预先设定的主要目检缺陷 xxx % 接受标准。这些结果表明,PPQ 批次未能充分证明工艺在可见异物缺陷方面的一致性、可重现性及持续受控状态。
观察项 2 / Observation 2
Your firm failed to adequately investigate the progressively increasing high visible particulate rejection rates identified during 100% visual inspection of the xxx mg/xxx ml PPQ batches. Specifically, to investigate the two xxx mg/xxx ml PPQ DP batches xxx xxx that exhibited visible particulate rejection rates exceeding the predefined visual inspection acceptance criterion of xxx %, xxx units from each batch's rejected unit pool of major defect were randomly selected for further identification. This represented xxx % and xxx % sampling from the major defect pools of the two PPQ batches respectively. The sampling of the studies had no documented justification to ensure that the sampled units were representative or scientifically appropriate. The investigation did not provide adequate scientific justification to support that current manufacturing operation is a controlled process. The high and variable visible particulate defects indicate a recurring manufacturing or contamination control issue. The investigation was inconclusive in determining the root cause of the high visible particulate defects in these batches.
【中文译文】你方未能充分调查 xxx mg/xxx ml PPQ 批次在 100% 目检中发现的逐步升高的高可见异物剔除率。具体而言,为调查两个可见异物剔除率超过预设目检接受标准 xxx % 的 xxx mg/xxx ml PPQ 制剂批次 xxx xxx,从每个批次的主要缺陷剔除单元池中随机选取 xxx 个单元进行进一步鉴定。这分别相当于从两个 PPQ 批次的主要缺陷池中抽取了 xxx % 和 xxx %。该研究的取样没有书面论证,无法确保所取单元具有代表性或在科学上适当。该调查未能提供充分的科学依据来支持当前生产操作处于受控状态。高且波动的可见异物缺陷表明存在反复出现的生产或污染控制问题。该调查在确定这些批次高可见异物缺陷的根本原因方面未得出明确结论。
观察项 3 / Observation 3
Your firm failed to maintain adequate quality oversight over changes to the established acceptance criterion for 100% visual inspection. Specifically, your firm retrospectively revised the visual inspection acceptance criterion to xxx % from xxx % as defined in the xxx mg/xxx mL PPQ protocol (PV-VP-000027), and the revision of visual inspection acceptance criterion was implemented retrospectively without an approved change control. Your firm did not adequately evaluate the potential impact of the revised criterion on product quality, batch disposition, process control, or the validity of the original acceptance criterion.
【中文译文】你方未能对 100% 目检既定接受标准的变更保持充分的质量监督。具体而言,你方追溯性地将 xxx mg/xxx mL PPQ 方案(PV-VP-000027)中规定的目检接受标准由 xxx % 修改为 xxx %,且该目检接受标准的修订未经批准的变更控制即追溯实施。你方未充分评估修订后标准对产品质量、批处置、工艺控制或原接受标准有效性的潜在影响。
观察项 4 / Observation 4
Your firm's cleaning validation programs for manufacturing equipment and components are inadequate in demonstrating that equipment used in drug substance and drug product manufacturing can be consistently cleaned to prevent contamination or carryover. Specifically,
【中文译文】你方对生产设备和部件开展的清洁验证方案不充分,未能证明用于原料药和制剂生产的设备能够被持续清洁到位,以防止污染或交叉残留。具体而言:
a. Your firm's xxx validations for xxx and xxx used in the manufacture of xxx drug substance did not include swab sampling or visual inspection of the internal product-contact surfaces of the xxx and xxx Your cleaning validation sampling plan did not provide adequate scientific justification demonstrating that rinse samples were representative of the most difficult to clean locations within the xxx
【中文译文】a. 你方对 xxx 原料药生产中使用的 xxx 和 xxx 开展的 xxx 验证,未包括对 xxx 和 xxx 内部接触产品表面的擦拭取样或目检。你方的清洁验证取样方案未提供充分的科学论证,证明淋洗样品能够代表 xxx 内部最难清洁的部位。
b. Your firm did not perform cleaning validation for indirect product contact equipment used on the filling line. Your cleaning verification studies of indirect product contact filling line equipment did not include testing or scientifically justified acceptance criteria for removal of xxx residues from relevant filling line components, including stopper handling and transferring equipment where xxx carryover may occur.
【中文译文】b. 你方未对灌装线上间接接触产品的设备进行清洁验证。你方对间接接触产品的灌装线设备开展的清洁确认研究,未包括去除相关灌装线部件(包括可能发生 xxx 残留的胶塞处理和转运设备)上 xxx 残留的检测或经科学论证的接受标准。
观察项 5 / Observation 5
During the filling of xxx drug product, xxx mg/xxx ml, xxx nl vial on May 13, 2026, an operator failed to set the xxx as indicated in step xxx of SOP-00273 xxx Standard Operating Procedure (version 14, effective date: April 16, 2026). As a result, the xxx settings of
【中文译文】2026年5月13日,在 xxx 制剂(xxx mg/xxx ml,xxx nl 西林瓶)灌装过程中,一名操作人员未能按照 SOP-00273 xxx 标准操作规程(第 14 版,生效日期:2026年4月16日)第 xxx 步的规定设置 xxx。结果导致 xxx 的 xxx 设置
xxx were observed at xxx respectively, contrary to the xxx settings of corresponding xxx at xxx for xxx ml vials as referenced in section xxx of SOP-00273. The operator confirmed that adjustments of the xxx settings of the xxx were not performed during any time of the operation. No written procedure is established on recording the xxx setting of xxx Additionally, the cover of the xxx xxx was cracked and was held together with transparent tape during operation.
【中文译文】xxx 分别被观察到处于 xxx,与 SOP-00273 第 xxx 节中针对 xxx ml 西林瓶所引用的相应 xxx 的 xxx 设置相反。操作人员确认,在整个操作过程中未对 xxx 的 xxx 设置进行任何调整。对于 xxx 的 xxx 设置,未建立书面程序进行记录。此外,xxx xxx 的盖子在操作期间出现裂纹,并用透明胶带固定。
观察项 6 / Observation 6
Your quality control laboratory procedures and controls for test and sample management are inadequate or not followed. Specifically,
【中文译文】你方质量控制实验室在检验和样品管理方面的程序与控制措施不充分或未得到遵守。具体而言:
a. Permission assigned to analysts in Empower chromatography software includes the privilege to view quantitation peak fields in review. This allows analysts to view area accounts and results at the time of integration. QC analysts were observed changing the integration parameters without saving interim results. There is no documented justification why the initially applied integration parameters were not suitable before changing the integration parameters.
【中文译文】a. Empower 色谱软件中分配给分析人员的权限包括在审核界面查看定量峰字段的权限。这使得分析人员能够在积分时查看峰面积和结果。观察到 QC 分析人员在未保存中间结果的情况下更改积分参数。在更改积分参数之前,没有书面论证说明最初应用的积分参数为何不适用。
西门:此项次是最近两年最常见的色谱缺陷之一,尤其今年经常出现,今年出现,我印象中不少于7次,此前有过类似分析
FDA483:国家级检查员的要求-Empower在Review窗口不得能看到数据预览,一个序列应保证积分方法一致
b. SOP-01655 and test record of size exclusion chromatography (SEC) of aggregates xxx xxx method do not specify how to verify the storage duration for the prepared samples stored in the xxx The xxx aggregates of xxx are sensitive to change of xxx A prolonged xxx of the sample may cause xxx degradation and method variability. SOP-01655 is developed to control xxx xxx of xxx Per SOP-01655, the prepared sample is allowed to be stored in xxx up to xxx
【中文译文】b. SOP-01655 及聚集体 xxx xxx 方法尺寸排阻色谱(SEC)检验记录未规定如何核实存放在 xxx 中的已制备样品的贮存时间。xxx 的 xxx 聚集体对 xxx 的变化敏感。样品 xxx 时间过长可能导致 xxx 降解和方法变异。制定 SOP-01655 是为了控制 xxx 的 xxx xxx。根据 SOP-01655,已制备样品允许在 xxx 中贮存至多 xxx。
c. Your QC sample management procedure is not adequate for sample reconciliation of the electronic system. Specifically, on May 12, 2026, Laboratory Information Management System (LIMS) showed that a total of xxx samples were historically located in the 2-8 °C refrigerator (QC-C-637) in QC physical chemical lab room xxx Analysts discard QC samples periodically by filling out the "Record for Discarding Remaining Test Samples (Form-00021)". QC samples were not reconciled in LIMS after disposal on April 30, 2026 and May 11, 2026.
【中文译文】c. 你方 QC 样品管理程序不足以实现电子系统的样品核对。具体而言,2026年5月12日,实验室信息管理系统(LIMS)显示,共有 xxx 个样品历史性地存放在 QC 理化实验室 xxx 房间的 2-8 °C 冰箱(QC-C-637)中。分析人员通过填写"剩余检验样品销毁记录(表单-00021)"定期销毁 QC 样品。2026年4月30日和2026年5月11日处置后,QC 样品未在 LIMS 中进行核对。
观察项 7 / Observation 7
Your firm failed to establish adequate controls to prevent unauthorized deletion of electronic laboratory data during data archiving process. Specifically, the deletion protection setting for xxx analyzer xxx was removed when IT was archiving electronic data from xxx to xxx. During audit on May 12, 2026, an operator demonstrated unauthorized deletion of data files (i.e., xxx from xxx analyzer xxx during data archiving.
【中文译文】你方未能建立充分的控制措施,防止数据归档过程中未经授权删除电子实验室数据。具体而言,IT 部门在将电子数据从 xxx 归档至 xxx 时,移除了 xxx 分析仪 xxx 的删除保护设置。在2026年5月12日的审计中,一名操作人员演示了在数据归档期间可未经授权删除 xxx 分析仪 xxx 的数据文件(即 xxx)。
观察项 8 / Observation 8
Your firm failed to adequately control non-process equipment located in drug substance manufacturing clean areas. Specifically, a xxx refrigerator is located in Building xxx Room xxx where drug substance formulation, xxx operations are performed. Your firm did not define the intended use or storage controls of the refrigerator, had no written procedure for routine cleaning and disinfection of the refrigerator, and did not perform risk assessment to justify its presence in the clean room or evaluated its potential contamination risk to processing operations.
【中文译文】你方未能充分控制位于原料药生产洁净区内的非工艺设备。具体而言,一xxx冰箱放置在开展原料药配制、xxx 操作的 Building xxx Room xxx 内。你方未规定该冰箱的预期用途或贮存控制措施,没有对该冰箱的日常清洁和消毒建立书面程序,也未开展风险评估以证明其存在于洁净室内的合理性,或评估其对工艺操作的潜在污染风险。
观察项 9 / Observation 9
Your firm failed to maintain adequate control and traceability of temperature monitoring sensors within the building management system. Specifically, during walkthrough inspection of Building/Equipment Management System (BMS/EMS) located in Building xxx room xxx on May 11, 2026, an alarm record at 13:03:25 on May 8, 2026 associated with sensor TT4038_2 for equipment QC-C-430 refrigerator could not be retrieved when a query was sent to the audit trail system. The firm stated that the sensor TT4038_2 displayed in the audit trail of the xxx product storage Equipment Parameter Monitoring System (ENG-E-140) did not match the actual sensor position. The firm admitted that during the configuration process after equipment location change (Change Control: PR44994), the engineer omitted the "Source" item tag in the audit trail and failed to update the tag from sensor TT4038_2 to sensor TT4039_1.
【中文译文】你方未能对楼宇管理系统中的温度监测传感器保持充分控制和可追溯性。具体而言,2026年5月11日,在对位于 Building xxx room xxx 的楼宇/设备管理系统(BMS/EMS)进行巡查检查时,向审计追踪系统发送查询后,无法检索到与设备 QC-C-430 冰箱传感器 TT4038_2 相关联的2026年5月8日 13:03:25 的报警记录。你方表示,xxx 产品贮存设备参数监测系统(ENG-E-140)审计追踪中显示的传感器 TT4038_2 与实际传感器位置不符。你方承认,在设备位置变更(变更控制:PR44994)后的配置过程中,工程师遗漏了审计追踪中的"来源"项标签,且未能将标签从传感器 TT4038_2 更新为传感器 TT4039_1。
观察项 10 / Observation 10
Procedures and practices intended to prevent contamination and maintain appropriate conditions within classified manufacturing areas are inadequate. Specifically,
【中文译文】旨在防止污染并维持分级生产区适当条件的程序和实践不充分。具体而言:
a. On May 17, 2026, an open biohazardous waste bag containing xxx waste material was observed lying directly on the floor in Grade C manufacturing Room xxx while a xxx xxx operation was in progress. Waste material was observed protruding from the open bag and exposed to the room environment. Room xxx is used for drug substance formulation, xxx xxx No bag rack, holder, or other container was used to secure the biohazardous waste bag and prevent exposure of the waste material to the classified manufacturing environment.
【中文译文】a. 2026年5月17日,在 C 级生产 Room xxx 内进行 xxx xxx 操作期间,观察到一只装有 xxx 废弃物的生物危害废弃物袋敞口直接放置在地板上。观察到废弃物从敞开的袋中露出并暴露于房间环境中。Room xxx 用于原料药配制、xxx xxx。现场未使用袋子支架、固定装置或其他容器来固定生物危害废弃物袋,以防止废弃物暴露于分级生产环境中。
b. On May 17, 2026, while observing xxx operation in Building xxx Grade C Room xxx, a xxx waste container containing waste xxx was observed being placed on the lower shelf of a xxx table which is not designated as a waste storage location.
【中文译文】b. 2026年5月17日,在观察 Building xxx 中 C 级 Room xxx 内的 xxx 操作时,观察到一只装有 xxx 废弃物的 xxx 废弃物容器被放置在 xxx 台的下层搁板上,而该位置并未被指定为废弃物存放地点。
观察项 11 / Observation 11
Your firm failed to investigate a laboratory sample handling error in a timely manner. Specifically, on May 4, 2026, batch record xxx recorded that an operator used a wrong sample to perform xxx testing at Step xxx of the xxx production bioreactor operation for xxx drug substance batch xxx and generated result xxx which was not related to batch xxx but saved with the actual IPC test results xxx xxx. No deviation was initiated until May 14, 2026 after inquired by inspector.
【中文译文】你方未能及时调查实验室样品处理错误。具体而言,2026年5月4日,批记录 xxx 记载一名操作人员在 xxx 原料药批次 xxx 的 xxx 生产生物反应器操作第 xxx 步使用了错误的样品进行 xxx 检验,并产生了与批次 xxx 无关的结果 xxx,且该结果与实际的 IPC 检验结果 xxx xxx 保存在一起。直到2026年5月14日检查员问询后,才启动偏差调查。
来源:BasicPharma搬砖工 · mp.weixin.qq.com